Efficacy of ayurveda medications, Brahmi vati and Saraswatarista, in generalized anxiety disorder- a randomized controlled trial.

IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Journal of Ayurveda and Integrative Medicine Pub Date : 2024-11-01 Epub Date: 2024-12-02 DOI:10.1016/j.jaim.2024.101033
Varsha B Gonugade, Sameeran S Chate, Basavaraj R Tubaki, Rajat Thakur
{"title":"Efficacy of ayurveda medications, Brahmi vati and Saraswatarista, in generalized anxiety disorder- a randomized controlled trial.","authors":"Varsha B Gonugade, Sameeran S Chate, Basavaraj R Tubaki, Rajat Thakur","doi":"10.1016/j.jaim.2024.101033","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ayurvedic intervention (Brahmi Vati with Saraswatarista) is explored for their possible role in management of Generalized Anxiety Disorder (GAD), a common psychiatric disorder.</p><p><strong>Objective: </strong>The objective of the study was to evaluate the efficacy of Brahmi Vati and Saraswatarista in GAD.</p><p><strong>Methods: </strong>Study is a randomized controlled clinical trial. Patients (n = 50) of GAD (Diagnostic and Statistical Manual of Mental Disorders (DSM-5 criteria), 18-60 years of age, either sex participated in the study. Participants were randomly divided into two groups. Group A, received escitalopram 10 mg/day for first 10 days followed by 20 mg/day for next 50 days. Group B, received Ayurvedic intervention (Brahmi Vati 500 mg thrice a day (TID) and Saraswatarista 10 ml TID) for 60 days. Assessments were with clinical parameters like Hamilton Anxiety Rating Scale (HARS), GAD 7 scale (GAD 7), Beck Depression Inventory scale (BDI), Epworth sleepiness scale (ESS), Pittsburgh Sleep Quality Index (PSQI), WHO Quality of Life- BREF (WHOQOL-BREF), Clinical Global Improvement scale (CGI) and UKU-Side effect scale (UKU). These clinical assessments were measured on every 15th day during the intervention. Haemoglobin, liver function test (LFT), serum creatinine, serum urea were assessed before and after the study.</p><p><strong>Results: </strong>Study results indicate that both the groups were comparable in HARS, GAD7, BDI, WHOQOL-Bref and CGI-Severity. Group B was better in PSQI (standard mean difference = 0.87, 95% CI: 0.28, 1.43), ESS (standard mean difference = 1.42, 95% CI: 0.78, 2.02), CGI [global improvement (standard mean difference = 0.82, 95% CI: 0.23,1.28) and efficacy index (standard mean difference = 0.97, 95% CI: 0.37,1.54)] and had better adverse events profile (standard mean difference = 0.79, 95% CI: 0.21, 1.36). Both the groups had a good safety profile assessed through liver and renal profiles.</p><p><strong>Conclusion: </strong>Ayurveda interventions has additional advantages likes improvements in sleep profile, lesser adverse events and better global improvement in management of GAD. CTRI Registration Number is CTRI/2020/09/027750.</p>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"101033"},"PeriodicalIF":1.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652770/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ayurveda and Integrative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jaim.2024.101033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Ayurvedic intervention (Brahmi Vati with Saraswatarista) is explored for their possible role in management of Generalized Anxiety Disorder (GAD), a common psychiatric disorder.

Objective: The objective of the study was to evaluate the efficacy of Brahmi Vati and Saraswatarista in GAD.

Methods: Study is a randomized controlled clinical trial. Patients (n = 50) of GAD (Diagnostic and Statistical Manual of Mental Disorders (DSM-5 criteria), 18-60 years of age, either sex participated in the study. Participants were randomly divided into two groups. Group A, received escitalopram 10 mg/day for first 10 days followed by 20 mg/day for next 50 days. Group B, received Ayurvedic intervention (Brahmi Vati 500 mg thrice a day (TID) and Saraswatarista 10 ml TID) for 60 days. Assessments were with clinical parameters like Hamilton Anxiety Rating Scale (HARS), GAD 7 scale (GAD 7), Beck Depression Inventory scale (BDI), Epworth sleepiness scale (ESS), Pittsburgh Sleep Quality Index (PSQI), WHO Quality of Life- BREF (WHOQOL-BREF), Clinical Global Improvement scale (CGI) and UKU-Side effect scale (UKU). These clinical assessments were measured on every 15th day during the intervention. Haemoglobin, liver function test (LFT), serum creatinine, serum urea were assessed before and after the study.

Results: Study results indicate that both the groups were comparable in HARS, GAD7, BDI, WHOQOL-Bref and CGI-Severity. Group B was better in PSQI (standard mean difference = 0.87, 95% CI: 0.28, 1.43), ESS (standard mean difference = 1.42, 95% CI: 0.78, 2.02), CGI [global improvement (standard mean difference = 0.82, 95% CI: 0.23,1.28) and efficacy index (standard mean difference = 0.97, 95% CI: 0.37,1.54)] and had better adverse events profile (standard mean difference = 0.79, 95% CI: 0.21, 1.36). Both the groups had a good safety profile assessed through liver and renal profiles.

Conclusion: Ayurveda interventions has additional advantages likes improvements in sleep profile, lesser adverse events and better global improvement in management of GAD. CTRI Registration Number is CTRI/2020/09/027750.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
印度草药治疗广泛性焦虑症的疗效——一项随机对照试验。
背景:阿育吠陀干预(Brahmi Vati与Saraswatarista)探讨其在管理广泛性焦虑症(GAD)中的可能作用,这是一种常见的精神障碍。目的:本研究旨在评价婆罗门梵和沙参对广泛性焦虑症的疗效。方法:采用随机对照临床试验。GAD(精神障碍诊断与统计手册(DSM-5标准))患者(n = 50),年龄18-60岁,男女不限。参与者被随机分为两组。A组,前10天服用艾司西酞普兰10mg /天,后50天服用20mg /天。B组给予阿育吠陀干预(Brahmi Vati 500 mg,每日3次(TID), saraswatista 10 ml TID),疗程60天。采用汉密尔顿焦虑评定量表(HARS)、GAD 7量表(GAD 7)、贝克抑郁量表(BDI)、Epworth嗜睡量表(ESS)、匹兹堡睡眠质量指数(PSQI)、WHO生活质量-BREF量表(WHOQOL-BREF)、临床总体改善量表(CGI)和UKU副作用量表(UKU)等临床参数进行评估。这些临床评估在干预期间每15天测量一次。研究前后分别测定血红蛋白、肝功能、血清肌酐、血清尿素。结果:两组在HARS、GAD7、BDI、WHOQOL-Bref、CGI-Severity指标上具有可比性。B组在PSQI(标准平均差值= 0.87,95% CI: 0.28, 1.43)、ESS(标准平均差值= 1.42,95% CI: 0.78, 2.02)、CGI[整体改善(标准平均差值= 0.82,95% CI: 0.23,1.28)和疗效指数(标准平均差值= 0.97,95% CI: 0.37,1.54)]方面较好,不良事件谱较好(标准平均差值= 0.79,95% CI: 0.21, 1.36)。两组都有良好的安全性,通过肝脏和肾脏评估。结论:阿育吠陀干预具有其他优势,如改善睡眠状况,减少不良事件,更好地改善广泛性焦虑症的管理。CTRI注册号为CTRI/2020/09/027750。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Ayurveda and Integrative Medicine
Journal of Ayurveda and Integrative Medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-
CiteScore
4.70
自引率
12.50%
发文量
136
审稿时长
30 weeks
期刊最新文献
Urine exosome biomarkers of obesity after Lekhana Basti treatment - Report of a pilot study. Mind relaxation effect of Jatamansi Taila Shirodhara on psychological distress in Triple Negative Breast Cancer (TNBC) patients - results of an open-labelled, randomised controlled clinical trial. Adjunct Ayurvedic treatment providing more than 10 years of disease-free survival in a rare case of male breast cancer patient with high-grade invasive ductal cell carcinoma - A Case Report. Interconnecting surgical science, art, philosophy and technology for holistic health. Coexisting pilonidal sinus and anal fistula: Successful management with minimal invasive Kshara Karma Technique and Ksharasutra therapy- A case report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1